Back to search results

NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer

This study is testing a new digital system called the NYU Electronic Patient Visit Assessment (ePVA) for people with head and neck cancer. This system helps doctors track your symptoms in real-time so they can provide quick support. We want to see if using the ePVA is more effective than usual care in managing symptoms. Success will be measured by how well your head and neck cancer symptoms are controlled, as reported by you, four weeks after you finish radiation therapy. You can join if you are 18 or older, have head and neck cancer, are receiving radiation therapy (with or without chemotherapy), and speak English or Spanish. This study aims to enroll 270 participants.

Study design
This is an interventional study comparing the NYU Electronic Patient Visit Assessment (ePVA) to usual care. The study plans to enroll 270 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your head and neck cancer symptoms will be assessed at 4 weeks after completing radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06030011

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

Recruiting
NAAges 18+InterventionalTreatment
The University of Texas Health Science Center, Houston
~270 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:NYU Electronic Patient Visit Assessment (ePVA)Usual Care

At a glance

Recruiting sites
2 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Head and neck cancer (HNC) symptoms as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)
Measured over 4 weeks after completing radiation therapy

Conditions

Head and Neck Cancer

Explore related trials

Malignant Head and Neck Neoplasm

Where it's being run

5 sites across 4 states
New York2
Kansas1
Pennsylvania1
Texas1

Study leadership

  • Janet H. Van Cleave, PhD, RN · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at Houston (UTHealth Houston)

Who to contact

Janet H. Van Cleave, PhD, RN
[email protected]
(713) 500-2000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals with histologically diagnosed head and neck cancer (HNC) undergoing curative radiation therapy with or without chemotherapy
English or Spanish speaking
Clinicians (i.e., physicians, nurses, dentists, physician assistants, social workers, nutritionists, speech swallow therapists) caring for patients with head and neck cancer at the participating institutions

Exclusion

Any medical condition that could limit the participant's ability to provide informed consent and complete the questionnaires.

What this trial measures

  • Head and neck cancer (HNC) symptoms as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)4 weeks after completing radiation therapy

    The EORTC QLQ-C30 and QLQ-H\&N35 will be used to measure head and neck cancer symptoms, such as social function, senses of taste and smell, and swallowing. The scores will be summed and then transformed to a single score ranging from 0=Best to 100=Worst.